-
- May 10, 2021
Rifapentine-based regimen may allow for shorter course in tuberculosis
Treatment with rifapentine-based regimen for 4 months was found to be noninferior to the standard 6-month regimen in patients with tuberculosis, according to a study.
In this open-label, phase 3, randomized, controlled trial, 2234 patients with newly diagnosed pulmonary tuberculosis were asse…
-
- May 07, 2021
Poor response to neoadjuvant chemotherapy predictive of recu...
Patients with localized Ewing sarcoma who have a poor pathologic or radiologic response to neoadjuva... -
- May 07, 2021
FDA grants accelerated approval to pembrolizumab for HER2-po...
he Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck &...
VIDEOS
- May 08, 2021
Emerging Therapies in Interstitial Lung Disease
-
May 08, 2021
The Impact of COVID-19 on…
-
May 08, 2021
Treating Interstitial Lung Disease
-
May 08, 2021
High-resolution CT in ILD
-
May 08, 2021
ILD: The importance of patient…
-
May 08, 2021
How common is misdiagnosis in ILD?
-
May 07, 2021
How are ILDs usually categorized?
May 07, 2021
How are ILDs usually categorized?
-
NORD Video: Alagille Syndrome
Mar 16, 2021
-
Understanding the Clinical Impact of Lupus…
Mar 15, 2021
-
Treatment Challenges in Lupus Nephritis
Mar 12, 2021
Conference Roundup
- Apr 13, 2021
Investigational therapy improves overall survival in metastatic uveal melanoma
Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at…
-
-
-
AMX0035 lower long-term risk of death in ALS
Mar 23, 2021
-
Continuing Medical Education
-
NORD: Giant Cell (Session 1)
Mar 23, 2020
-
-
NORD: Spinal Muscular Atrophy
Mar 23, 2020
-
NORD: Pediatric Epilepsy
Mar 23, 2020
Journal Scan
- May 10, 2021
Rifapentine-based regimen may allow for shorter course in tuberculosis
Treatment with rifapentine-based regimen for 4 months was found to be noninferior to the standard 6-month regimen in patients with tuberculosis, according to a study.
In this open-label, phase…
Trending Topics
- May 06, 2021
FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer
he Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2…
Resources
-
Tools
- Find Zebra
- Genetic and Rare Diseases Information Center
- National Organization for Rare Disorders (NORD)
- National Organization for Rare Disorders (NORD): Patient Assistance Programs
- NCATS Toolkit for Patient-Focused Therapy Development
- NCCN Guidelines
- NORD Online Physician Guides
- Orphan Products Clinical Trials Grants Program
- Orphanet
- Rare Diseases Registry Program
-
Patient Tools
- testing post